Literature DB >> 3095243

Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

S C Szu, R Schneerson, J B Robbins.   

Abstract

A conjugate, composed of the cell wall polysaccharide (C polysaccharide) of Streptococcus pneumoniae and bovine serum albumin (BSA), was prepared with the bifunctional agent N-succinimidyl-3-(2-pyridyldithio)-propionate. Analysis with monoclonal antibodies provided evidence that the phosphocholine (PC) moiety of the C polysaccharide was retained during the conjugation procedure. The C polysaccharide-BSA conjugate elicited antibodies to C polysaccharide in rabbits; no PC-specific antibodies were detected in globulins prepared from these hyperimmune sera obtained early and late after a second immunization. Rabbit hyperimmune sera were taken after multiple intravenous injections of the pneumococcus strain SRC-2, which has a capsulelike structure composed of the C polysaccharide. Globulin prepared from these antisera had both C polysaccharide- and PC-specific antibodies. Antibodies to C polysaccharide elicited by the C polysaccharide-BSA conjugate failed to protect mice against intraperitoneal challenge with a strain of type 3 or type 6A pneumococci. The anti-SRC-2 globulin conferred protection against both of these pneumococcal strains. Absorption of the SRC-2 globulin with C polysaccharide, however, failed to change its protective activity. These data provide evidence that antibodies to the C polysaccharide do not confer immunity against infection of mice with encapsulated pneumococci inoculated by the intraperitoneal route.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095243      PMCID: PMC260182          DOI: 10.1128/iai.54.2.448-455.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  The preparation and enzymatic hydrolysis of reduced and S-carboxymethylated proteins.

Authors:  A M CRESTFIELD; S MOORE; W H STEIN
Journal:  J Biol Chem       Date:  1963-02       Impact factor: 5.157

2.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

3.  Horse anti-pneumococcal immunoglobulins. II. Specific mouse protective activity.

Authors:  W C Hill; J B Robbins
Journal:  Proc Soc Exp Biol Med       Date:  1966-10

4.  Specificity for phosphorylcholine of six murine myeloma proteins reactive with Pneumococcus C polysaccharide and beta-lipoprotein.

Authors:  M A Leon; N M Young
Journal:  Biochemistry       Date:  1971-04-13       Impact factor: 3.162

5.  Quantitative studies of the specificity of anti-pneumococcal antibodies, types 3 and 8. IV. Binding of labeled hexasaccharides derived from S3 by anti-S3 antibodies and their Fab fragments.

Authors:  M Katz; A M Papenheimer
Journal:  J Immunol       Date:  1969-09       Impact factor: 5.422

6.  The immunological responses observed in field studies in Africa with group A meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; J Etienne; W R Sanborn; R Triau; B Cvjetanović
Journal:  Prog Immunobiol Stand       Date:  1971

7.  A method for producing specific antisera with small doses of immunogen.

Authors:  J Vaitukaitis; J B Robbins; E Nieschlag; G T Ross
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

8.  Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent.

Authors:  J Carlsson; H Drevin; R Axén
Journal:  Biochem J       Date:  1978-09-01       Impact factor: 3.857

9.  Spatial requirements between haptenic and carrier determinants for T-dependent antibody responses.

Authors:  S Fong; D E Nitecki; R M Cook; J W Goodman
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

10.  Capsulation of pneumococcus with soluble C-like (Cs) polysaccharide. I. Biological and genetic properties of Cs pneumococcal strains.

Authors:  D L Bornstein; G Schiffman; H P Bernheimer; R Austrian
Journal:  J Exp Med       Date:  1968-12-01       Impact factor: 14.307

View more
  24 in total

1.  Pneumococcal antigens and serum antibody responses in experimentally induced sinusitis.

Authors:  K M Westrin; A Freijd; P Stierna
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

2.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates.

Authors:  C Peeters; A M Tenbergen-Meekes; J Poolmann; B Zegers; G Rijkers
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

4.  Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide.

Authors:  Ying-Jie Lu; Ian Chr Skovsted; Claudette M Thompson; Porter W Anderson; Richard Malley
Journal:  Microb Pathog       Date:  2009-07-03       Impact factor: 3.738

Review 5.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

6.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

7.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

8.  Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.

Authors:  M B Marques; D L Kasper; A Shroff; F Michon; H J Jennings; M R Wessels
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

9.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.

Authors:  A Fattom; W F Vann; S C Szu; A Sutton; X Li; D Bryla; G Schiffman; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.